Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration

Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises levels of progranulin in people who have a shortage of this vital protein for genetic reasons, potentially stopping them developing symptomatic frontotemporal dementia (FTD) VES001… Continue reading Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration

Implantica publishes Interim Report January – September 2025 (Q3)

VADUZ, Liechtenstein, Oct. 31, 2025 /PRNewswire/ — RefluxStop® Nears FDA Approval – Strong Momentum Toward US Market Entry Significant events in the third quarter of 2025 Received positive feedback from the FDA on the final PMA Module 3 submission Expanded production by 10,000 RefluxStop® units, ensuring readiness for rapid U.S. scale-up following FDA approval Built… Continue reading Implantica publishes Interim Report January – September 2025 (Q3)

FastGPT Emerges as One of the Best No-code and Open-source AI Agent Builders for 2025, Empowering Enterprises to Build Smarter Workflows

SINGAPORE, Oct. 31, 2025 /PRNewswire/ — As artificial intelligence continues to revolutionize industries, businesses are increasingly seeking ways to integrate AI-driven automation and intelligence into their operations. FastGPT, positioned as an Enterprise-class AI Agent Builder with no code + low code dual-mode support, has quickly emerged as one of the most powerful AI platforms for… Continue reading FastGPT Emerges as One of the Best No-code and Open-source AI Agent Builders for 2025, Empowering Enterprises to Build Smarter Workflows

Loomis Interim Report January – September 2025

STOCKHOLM, Oct. 31, 2025 /PRNewswire/ — Strong operating cash flow and operating margin (EBITA%) We had a strong performance in the third quarter. Revenues reached SEK 7.6 billion with an organic growth of 3.9 percent. Acquisitions contributed to growth while the strengthening of the SEK had a materially negative impact on revenue for all segments.… Continue reading Loomis Interim Report January – September 2025

Correction: Bioretec Ltd’s Half-year report 2025

Bioretec Ltd  Company release 31 October 2025 at 8.30 a.m. EET TAMPERE, Finland, Oct. 31, 2025 /PRNewswire/ — Bioretec announced on 27 October 2025 that it will adjust and restate its previously reported figures for H1/2025. The adjustment and restatement is related to the sales and distribution agreement with Tri-State Biologics (“TSB”), originally announced on 22 November… Continue reading Correction: Bioretec Ltd’s Half-year report 2025

Tetragon Financial Group Limited September 2025 Monthly Factsheet

LONDON, Oct. 31, 2025 /PRNewswire/ — Tetragon has released its Monthly Factsheet for September 2025. Net Asset Value: $3,886m Fully Diluted NAV per Share: $42.19 Share Price (TFG NA): $19.30 Monthly NAV per Share Total Return: 7.1% Monthly Return on Equity: 8.2% Most Recent Quarterly Dividend: $0.11 Dividend Yield: 2.3% Please refer to important disclosures on… Continue reading Tetragon Financial Group Limited September 2025 Monthly Factsheet

Correction: Bioretec Ltd’s Half-year report 2025

Bioretec Ltd  Company release 31 October 2025 at 8.30 a.m. EET TAMPERE, Finland, Oct. 31, 2025 /PRNewswire/ — Bioretec announced on 27 October 2025 that it will adjust and restate its previously reported figures for H1/2025. The adjustment and restatement is related to the sales and distribution agreement with Tri-State Biologics (“TSB”), originally announced on 22 November… Continue reading Correction: Bioretec Ltd’s Half-year report 2025

Aker Solutions ASA: Third-Quarter Results 2025

OSLO, Norway, Oct. 31, 2025 /PRNewswire/ — Aker Solutions has delivered strong growth and solid margins in the third quarter of 2025. Several milestones have been met on the project portfolio in the period. The company now expects revenues in 2025 to exceed NOK 60 billion. 3Q 2025 Financial Highlights  (excluding special items) Revenue NOK… Continue reading Aker Solutions ASA: Third-Quarter Results 2025